3Montoya JG,Giraldo LF,Efron B,et al.Infectious complications among 620 consecutive heart transplant patients at Stanford University Medical Center.Clin Infect Dis,2001,33 :629-640.
5Reichenspurner H,Gamberg P,Nitschke M,et al.Significant reduction in the number of fungal infections after lung,heart lung,and heart transplantation using aerosolized amphotericin B prophylaxis.Transplant Proc,1997,29:627-628.
2[1]Patterson JE, Peters J, Calhoon JH et al. Investigation and control of aspergillosis and other filamentous fungal infections in solid organ transplant recipients [J]. Transpl Infect Dis, 2000;2(1): 22-28.
3[2]Patterson JE. Epidemiology of fungal infections in solid organ transplant patients [J]. Transpl Infect Dis, 1999;1(4):229-236.
4Kusne SJ,Torre-Cisneros R,Manez W.Factors associated with invasive lung aspergillosis and the significance of positive aspergillus culture after liver transplantation[].The Journal of Infectious Diseases.1992
5Altiparmak MR,Apaydin S,Trablus S,et al.Systemic fungal infections after renal transplantation[].Scandinavian Journal of Infectious Diseases.2002
6Fisher NC,Singhal SJ,Miller JG.Fungal infection and liposomal amphotericin B therapy in liver transplantation: a 2 year review[].Journal of Antimicrobial Chemotherapy.1999
7Walsh TJ,Finberg RW,Arndt C,et al.Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia[].The New England Journal of Medicine.1999
8Ralph ED,Barber KR,Grant CW.Liposomal amphotericin B: an effective, nontoxic, preparation for the treatment of urinary tract infections caused by candida albicans[].American Journal of Nephrology.1991
